Albireo Pharma Inc (ALBO):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Albireo Pharma Inc (ALBO) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7226
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Albireo Pharma Inc (Albireo), formerly Biodel Inc., focuses on the development and commercialization of innovative bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal (GI) disorders and diseases where inappropriate flow of bile causes severe medical conditions for which there is high unmet need. The company’s lead product candidate, A4250 is a novel, minimally absorbed, orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor. The product is in a Phase III clinical trial for progressive familial intrahepatic cholestasis (PFIC), a rare, life-threatening genetic disorder affecting young children and potentially other orphan pediatric liver diseases. Albireo is located in Boston, Massachusetts, the US.

Albireo Pharma Inc (ALBO) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Albireo Pharma Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Albireo Pharma Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Albireo Pharma Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Albireo Pharma Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Albireo Pharma Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Albireo Pharma Inc, Medical Equipment, Deal Details 10
Equity Offering 10
Albireo Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 10
Albireo Pharma Raises USD74.8 Million in Public Offering of Shares 12
Albireo Pharma Raises USD19.2 Million in Public Offering of Shares 14
Albireo Pharma Inc – Key Competitors 15
Albireo Pharma Inc – Key Employees 16
Albireo Pharma Inc – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Financial Announcements 18
Aug 07, 2018: Albireo reports second quarter 2018 financial results 18
May 17, 2018: Albireo Provides First Quarter 2018 Business Update 20
Mar 15, 2018: Albireo Reports Fourth Quarter and Year-End 2017 Financial Results 21
Nov 14, 2017: Albireo Reports Third Quarter 2017 Financial Results 23
Aug 21, 2017: Albireo Reports Second Quarter 2017 Financial Results 25
May 10, 2017: Albireo Reports First Quarter 2017 Financial Results 27
Mar 14, 2017: Albireo Reports 2016 Financial Results 29
Corporate Communications 31
Oct 10, 2018: Albireo appoints Simon Harford as chief financial officer and treasurer 31
Jul 25, 2018: Albireo appoints Patrick Horn as Chief Medical Officer 32
Jun 18, 2018: Albireo Names Jason G. Duncan As General Counsel And Secretary 33
Jun 08, 2018: Albireo Names Anne Klibanski and Stephanie Okey As Board Directors 34
Sep 28, 2017: Albireo Elects Roger Jeffs to Board of Directors 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Albireo Pharma Inc, Medical Equipment, Key Facts, 2017 2
Albireo Pharma Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Albireo Pharma Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Albireo Pharma Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Albireo Pharma Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Albireo Pharma Inc, Deals By Market, 2012 to YTD 2018 8
Albireo Pharma Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Albireo Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 10
Albireo Pharma Raises USD74.8 Million in Public Offering of Shares 12
Albireo Pharma Raises USD19.2 Million in Public Offering of Shares 14
Albireo Pharma Inc, Key Competitors 15
Albireo Pharma Inc, Key Employees 16
Albireo Pharma Inc, Other Locations 17
Albireo Pharma Inc, Subsidiaries 17

List of Figures
Albireo Pharma Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Albireo Pharma Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Albireo Pharma Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Albireo Pharma Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Albireo Pharma Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Albireo Pharma Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Albireo Pharma Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Albireo Pharma Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Albireo Pharma Inc (ALBO):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Verona Pharma Plc (VRNA):企業の財務・戦略的SWOT分析
    Verona Pharma Plc (VRNA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Filtration Group Corp:企業の戦略的SWOT分析
    Filtration Group Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Emera Inc.:戦略・SWOT・企業財務分析
    Emera Inc. - Strategy, SWOT and Corporate Finance Report Summary Emera Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Infinity Pharmaceuticals Inc (INFI):製薬・医療:M&Aディール及び事業提携情報
    Summary Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company that discovers and develops small molecule therapeutics for the treatment of cancer. The company’s pipeline candidate: IPI-549 selectively inhibits PI3K-gamma to reprogram tumor-associated macrophages and …
  • Crownhaitai Holdings Co Ltd:企業の戦略・SWOT・財務情報
    Crownhaitai Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Crownhaitai Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Trustwave Holdings Inc:企業の戦略的SWOT分析
    Trustwave Holdings Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Yamaha Motor Co Ltd (7272):企業の財務・戦略的SWOT分析
    Yamaha Motor Co Ltd (7272) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Tulane University:製薬・医療:M&Aディール及び事業提携情報
    Summary Tulane University (Tulane) is an educational service provider that provides biomedical courses and research programs. The university provides educational courses in the fields of architecture, business, law, liberal arts, medicine, public health and tropical medicine, science, engineering, a …
  • Autodesk Inc:企業のM&A・事業提携・投資動向
    Autodesk Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Autodesk Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Medifirst Solutions Inc (MFST):医療機器:M&Aディール及び事業提携情報
    Summary Medifirst Solutions Inc (Medifirst Solutions) is a developer of non-invasive methods and technology for healthcare sector. The company’s flagship product includes the time machine infrared laser TTML-8102000 - 810/830nm, which treats patients suffering from various chronic pain conditions in …
  • Chemring Energetics UK Ltd:企業の戦略・SWOT・財務情報
    Chemring Energetics UK Ltd - Strategy, SWOT and Corporate Finance Report Summary Chemring Energetics UK Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Tourmaline Oil Corp.:企業のM&A・事業提携・投資動向
    Tourmaline Oil Corp. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tourmaline Oil Corp. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Huawei Technologies Co Ltd:企業の戦略的SWOT分析
    Huawei Technologies Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Vonage Holdings Corp:企業の戦略・SWOT・財務分析
    Vonage Holdings Corp - Strategy, SWOT and Corporate Finance Report Summary Vonage Holdings Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Cooperativa Muratori & Cementisti C.M.C di Ravenna:企業の戦略・SWOT・財務分析
    Cooperativa Muratori & Cementisti C.M.C di Ravenna - Strategy, SWOT and Corporate Finance Report Summary Cooperativa Muratori & Cementisti C.M.C di Ravenna - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's struct …
  • Destiny Pharma Plc (DEST):製薬・医療:M&Aディール及び事業提携情報
    Summary Destiny Pharma Plc (Destiny Pharma), formerly Destiny Pharma Ltd, a subsidiary of Destiny Pharma Holdings Ltd is a drug development and discovery company that offers commercial exploitation and clinical development of the antibacterial products. The company provides XF drug platform to addre …
  • Brambles Limited (BXB):企業の財務・戦略的SWOT分析
    Brambles Limited (BXB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Malaysian Pacific Industries Berhad (MPI):企業の財務・戦略的SWOT分析
    Malaysian Pacific Industries Berhad (MPI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Salesforce.Com Inc (CRM):企業の財務・戦略的SWOT分析
    Salesforce.Com Inc (CRM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Dynatronics Corp (DYNT):医療機器:M&Aディール及び事業提携情報
    Summary Dynatronics Corp (Dynatronics) is a medical device company that offers rehab technology and equipment solutions. The company offers modalities, hot and cold therapy, clinical accessories, body positioning, sports medicine, orthopedics, hand therapy, strength equipment, treatment tables and r …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆